Recent advances in neoantigen vaccines for treating non‐small cell lung cancer
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recent advances in neoantigen vaccines for treating non‐small cell lung cancer
Authors
Keywords
-
Journal
Thoracic Cancer
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2023-10-31
DOI
10.1111/1759-7714.15126
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer
- (2022) Katy McCann et al. Journal for ImmunoTherapy of Cancer
- Immunotherapy for ALK-Rearranged Non-Small Cell Lung Cancer: Challenges Inform Promising Approaches
- (2021) Kamya Sankar et al. Cancers
- Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations
- (2021) Fenge Li et al. Journal for ImmunoTherapy of Cancer
- Cancer vaccines: Targeting KRAS-driven cancers
- (2020) Ying Zhang et al. Expert Review of Vaccines
- A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer
- (2020) Patrick A. Ott et al. CELL
- Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors
- (2019) Fangjun Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Endogenous CD4+ T Cells Recognize Neoantigens in Lung Cancer Patients, Including Recurrent Oncogenic KRAS and ERBB2 (Her2) Driver Mutations
- (2019) Joshua R. Veatch et al. Cancer Immunology Research
- Clinical and immunological implications of frameshift mutations in lung cancer
- (2019) Young Kwang Chae et al. Journal of Thoracic Oncology
- Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment
- (2019) Michael Fehlings et al. Journal for ImmunoTherapy of Cancer
- Immunogenicity of Del19 EGFR mutations in Chinese patients affected by lung adenocarcinoma
- (2019) Deng Pan et al. BMC IMMUNOLOGY
- MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design
- (2018) Weijing Cai et al. BMC GENOMICS
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
- (2017) Ugur Sahin et al. NATURE
- An immunogenic personal neoantigen vaccine for patients with melanoma
- (2017) Patrick A. Ott et al. NATURE
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles
- (2017) Ju Hwan Cho Immune Network
- Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer
- (2016) Takahiro Karasaki et al. Journal of Thoracic Oncology
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
- (2016) Valsamo Anagnostou et al. Cancer Discovery
- Rapid tumor regression in an Asian lung cancer patient following personalized neo-epitope peptide vaccination
- (2016) Fenge Li et al. OncoImmunology
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review
- (2015) P.M. Ellis et al. Current Oncology
- Mutant MHC class II epitopes drive therapeutic immune responses to cancer
- (2015) Sebastian Kreiter et al. NATURE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Immunogenicity of somatic mutations in human gastrointestinal cancers
- (2015) E. Tran et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
- (2014) E. Tran et al. SCIENCE
- Immunotherapeutic Agents in Non-small-cell Lung Cancer Finally Coming to the Front Lines
- (2014) Rossana Ruiz et al. Current Oncology Reports
- ALK inhibitors in the treatment of advanced NSCLC
- (2013) Cesare Gridelli et al. CANCER TREATMENT REVIEWS
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers
- (2012) S. Dogan et al. CLINICAL CANCER RESEARCH
- KIF5B-RET fusions in lung adenocarcinoma
- (2012) Takashi Kohno et al. NATURE MEDICINE
- Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial
- (2011) Elisabeth Quoix et al. LANCET ONCOLOGY
- A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer
- (2010) Rodryg Ramlau et al. Journal of Thoracic Oncology
- Targeted therapies for non-small cell lung cancer
- (2009) Wolfram C.M. Dempke et al. LUNG CANCER
- Combining an EGF-based Cancer Vaccine With Chemotherapy in Advanced Nonsmall Cell Lung Cancer
- (2008) Elia Neninger et al. JOURNAL OF IMMUNOTHERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More